References and Notes
<A NAME="RD25106ST-1">1</A>
RRL communication No. SCL-6/07.
<A NAME="RD25106ST-2">2</A>
Sanghvi YS.
Bhattacharya BK.
Kini GD.
Matsumoto SS.
Larson SB.
Jolley WB.
Robins RK.
Revankar GR.
J. Med. Chem.
1990,
33:
336
<A NAME="RD25106ST-3">3</A>
Chen MD.
Lu SJ.
Yuag GP.
Yang SY.
Du XL.
Heterocycl. Commun.
2000,
6:
421
<A NAME="RD25106ST-4">4</A>
Sherement EA.
Tomanov RI.
Trukhin EV.
Berestovitskaya VM.
Russ. J. Org. Chem.
2004,
40:
594
<A NAME="RD25106ST-5">5</A>
Allais A, and
Meier J. inventors; Ger. Offen., 1815467.
<A NAME="RD25106ST-6">6</A>
Banu KM.
Dinakar A.
Ananthanarayanan C.
Indian J. Pharm. Sci.
1999,
4:
202
<A NAME="RD25106ST-7A">7a</A>
Meier R. inventors; Eur. Patent 199262.
<A NAME="RD25106ST-7B">7b</A>
Meier R. inventors; US Patent 4789680.
<A NAME="RD25106ST-8">8</A>
Passannanti A.
Diana P.
Barraja P.
Mingoia F.
Lauria A.
Cirrincione G.
Heterocycles
1998,
48:
1229
<A NAME="RD25106ST-9">9</A>
Jilino M.
Stevens FG.
J. Chem. Soc, Perkin Trans. 1
1998,
1677
<A NAME="RD25106ST-10">10</A>
Diana GD, and
Nitz JJ. inventors; Eur. Patent 566199.
<A NAME="RD25106ST-11">11</A>
Manfredini S.
Vicentini CB.
Manfrini M.
Bianchi N.
Rutigliano C.
Mischiati C.
Gambari R.
Bioorg. Med. Chem.
2000,
8:
2343
<A NAME="RD25106ST-12">12</A>
Danoun S.
Baziard-Mouysset G.
Stigliani J.
Payard M.
Selkti M.
Viossat B.
Tomas A.
Heterocycl. Commun.
1998,
4:
45
<A NAME="RD25106ST-13">13</A>
Biagi G.
Calderone V.
Giorgi I.
Livi O.
Martinotti E.
Martelli A.
Nardi A.
Farmaco
2004,
59:
397
<A NAME="RD25106ST-14A">14a</A>
Bourne Y.
Kolb HC.
Radic Z.
Sharpless KB.
Taylor P.
Marchot P.
Proc. Natl. Acad. Sci. U.S.A.
2004,
101:
1449
<A NAME="RD25106ST-14B">14b</A>
Lewis WG.
Green LG.
Grynszpan F.
Radic Z.
Carlier PR.
Taylor P.
Finn MG.
Sharpless KB.
Angew. Chem. Int. Ed.
2002,
41:
1053
<A NAME="RD25106ST-15">15</A>
Amantini D.
Fringuelli F.
Piermatti O.
Pizzo F.
Zunino E.
Vaccaro L.
J. Org. Chem.
2005,
70:
6526
<A NAME="RD25106ST-16">16</A>
Rostovtsev VV.
Green LG.
Fokin VV.
Sharpless KB.
Angew. Chem. Int. Ed.
2002,
41:
2596 ; Angew. Chem.
2002,
114:
2708
<A NAME="RD25106ST-17">17</A>
Wu YM.
Deng J.
Li YL.
Chen QY.
Synthesis
2005,
1314
<A NAME="RD25106ST-18">18</A>
Liu D.
Gao W.
Dai Q.
Zhang X.
Org. Lett.
2005,
7:
4907
<A NAME="RD25106ST-19">19</A>
Savini L.
Massarelli P.
Chiasserini L.
Pellerano C.
Bruni G.
Farmaco
1994,
49:
633
<A NAME="RD25106ST-20">20</A>
Holla BS.
Mahalinga M.
Karthikeyan MS.
Poojary B.
Akberali PM.
Kumari NS.
Eur. J. Med. Chem.
2005,
40:
1173
<A NAME="RD25106ST-21">21</A>
Rogue DR.
Neill JL.
Antoon JW.
Stevens EP.
Synthesis
2005,
2497
<A NAME="RD25106ST-22A">22a</A>
Akimova GS.
Chistokletov VN.
Petrov AA.
Zh. Org. Khim.
1967,
3:
968
<A NAME="RD25106ST-22B">22b</A>
Akimova GS.
Chistokletov VN.
Petrov AA.
Zh. Org. Khim.
1967,
3:
2241
<A NAME="RD25106ST-22C">22c</A>
Akimova GS.
Chistokletov VN.
Petrov AA.
Zh. Org. Khim.
1968,
4:
389
<A NAME="RD25106ST-23">23</A>
Wang Z.-X.
Qin H.-L.
Chem. Commun.
2003,
2450
<A NAME="RD25106ST-24">24</A>
Krasinski A.
Fokin VV.
Sharpless KB.
Org. Lett.
2004,
8:
1237
<A NAME="RD25106ST-25">25</A>
Schlenk W.
Chem. Ber.
1929,
62B:
920
<A NAME="RD25106ST-26">26</A>
In a typical procedure, to a suspension of magnesium turnings (1.6 g, 0.07 mol) in
anhyd THF with mercury(II) chloride (10 mg, 0.125 w/w of propargyl bromide) was added
propargyl bromide (7.5 mL of an 80 wt% solution in toluene, 0.07 mol) in small portions
while stirring the reaction mixture at r.t. (Note: A small crystal of iodine is generally
required to promote formation of the Grignard reagent). The mixture was stirred at
r.t. for 15 min to give a cloudy light green solution. The allenylmagnesium bromide
generated as above was cooled to ambient temperature and to it was added dropwise
a solution of p-methoxyphenyl azide (1 g, 0.007 mol) and stirring was continued at ambient temperature
for 10 min followed by quenching with an aq NH4Cl solution (10 mL) and diluting with EtOAc (50 mL). The organic layer was separated
and the aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic layers
were dried (anhyd Na2SO4) and evaporated under reduced pressure to afford the crude product which was subjected
to chromatography (basic aluminum oxide, elution: n-hexane-EtOAc gradient) to afford pure 5-but-3-yn-1-yl-1-(4-methoxyphenyl)-1H-1,2,3-triazole as a brown colored syrupy liquid (1.066 g,70%).
IR: 3293, 2957, 2925, 2855, 1722, 1597, 1546, 1501, 1457, 1253, 1120, 1092, 1069,
917, 765, 693, 650 cm-1. 1H NMR (CDCl3): δ = 2.05 (t, J = 2.5 Hz, 1 H), 2.50 (m, 2 H), 2.90 (t, J = 7.3 Hz, 2 H), 3.92 (s, 3 H), 7.30 (d, J = 8.9 Hz, 2 H), 7.45 (d, J = 8.9 Hz, 2 H ), 7.80 (s, 1 H). 13C NMR (500 MHz, CDCl3): δ = 17.83, 22.97, 55.64, 70.07, 81.81, 114.70, 126.84, 128.79, 132.48, 136.34,
162.51. ESI-MS: m/z = 227 [M+], 250 [M + Na]. Anal. Calcd for C13H13N3O: C, 68.71; H, 5.77; N, 18.49; O, 7.04. Found: C, 68.60; H, 5.81; N, 18.60; O, 6.99.